PURPOSE: To report early adverse events and patient-reported outcomes (PROs) of 3-fraction intracavitary catheter-based partial breast brachytherapy (ICBB). MATERIALS AND METHODS: Eligible women ≥50 years of age with ≤2.5-cm, lymph node-negative invasive or in situ breast cancer underwent breast-conserving surgery and placement of a brachytherapy applicator. ICBB was initiated on the second weekday after surgery and prescribed to 21 Gy in 3 once-daily fractions. Common Terminology Criteria for Adverse Events, version 4.0; 10-point linear analog scale assessment; the PRO version of the Common Terminology Criteria for Adverse Events; and the Harvard Breast Cosmesis Scale were used for provider and patient-reported assessments. RESULTS: Seventy-three women were treated for invasive (79%) or in situ (21%) breast cancer. The median time to completion of surgery and radiation therapy was 6 days. After 14-months median follow-up, 2 patients (3%) had developed breast infections that resolved with oral antibiotics. There was no other treatment-associated adverse event grade ≥2. The grade 1 seroma rate at 3 months was 20%, which dropped to 8% at 12 months; no events required intervention. At 12 months, 91% of patients reported an overall quality of life score as ≥8 of 10, and patient-reported cosmesis was good or excellent in 95%. All patients are alive without relapse at the last follow-up. CONCLUSIONS: Three-fraction ICBB is associated with low rates of early provider and patient- reported adverse events and compares favorably with early outcomes of more protracted ICBB regimens, including twice-daily (3.4 Gy × 10) fractionation studied in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-39. Further investigation is warranted.
PURPOSE: To report early adverse events and patient-reported outcomes (PROs) of 3-fraction intracavitary catheter-based partial breast brachytherapy (ICBB). MATERIALS AND METHODS: Eligible women ≥50 years of age with ≤2.5-cm, lymph node-negative invasive or in situ breast cancer underwent breast-conserving surgery and placement of a brachytherapy applicator. ICBB was initiated on the second weekday after surgery and prescribed to 21 Gy in 3 once-daily fractions. Common Terminology Criteria for Adverse Events, version 4.0; 10-point linear analog scale assessment; the PRO version of the Common Terminology Criteria for Adverse Events; and the Harvard Breast Cosmesis Scale were used for provider and patient-reported assessments. RESULTS: Seventy-three women were treated for invasive (79%) or in situ (21%) breast cancer. The median time to completion of surgery and radiation therapy was 6 days. After 14-months median follow-up, 2 patients (3%) had developed breast infections that resolved with oral antibiotics. There was no other treatment-associated adverse event grade ≥2. The grade 1 seroma rate at 3 months was 20%, which dropped to 8% at 12 months; no events required intervention. At 12 months, 91% of patients reported an overall quality of life score as ≥8 of 10, and patient-reported cosmesis was good or excellent in 95%. All patients are alive without relapse at the last follow-up. CONCLUSIONS: Three-fraction ICBB is associated with low rates of early provider and patient- reported adverse events and compares favorably with early outcomes of more protracted ICBB regimens, including twice-daily (3.4 Gy × 10) fractionation studied in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-39. Further investigation is warranted.
Authors: Timothy J Whelan; Jean-Philippe Pignol; Mark N Levine; Jim A Julian; Robert MacKenzie; Sameer Parpia; Wendy Shelley; Laval Grimard; Julie Bowen; Himu Lukka; Francisco Perera; Anthony Fyles; Ken Schneider; Sunil Gulavita; Carolyn Freeman Journal: N Engl J Med Date: 2010-02-11 Impact factor: 91.245
Authors: Laurie W Cuttino; Douglas W Arthur; Frank Vicini; Dorin Todor; Thomas Julian; Nitai Mukhopadhyay Journal: Int J Radiat Oncol Biol Phys Date: 2014-10-13 Impact factor: 7.038
Authors: Rachel Rabinovitch; Jennifer Moughan; Frank Vicini; Helen Pass; John Wong; Susan Chafe; Ivy Petersen; Douglas W Arthur; Julia White Journal: Int J Radiat Oncol Biol Phys Date: 2016-09-03 Impact factor: 7.038
Authors: Alex B Haynes; Elizabeth S Bloom; Isabelle Bedrosian; Henry M Kuerer; Rosa F Hwang; Mark F Munsell; Roy F Chemaly; Linda S Graviss; Abigail S Caudle; Kelly K Hunt; Welela Tereffe; Simona F Shaitelman; Gildy V Babiera Journal: Ann Surg Oncol Date: 2014-04-16 Impact factor: 5.344
Authors: Vratislav Strnad; Oliver J Ott; Guido Hildebrandt; Daniela Kauer-Dorner; Hellen Knauerhase; Tibor Major; Jaroslaw Lyczek; Jose Luis Guinot; Jürgen Dunst; Cristina Gutierrez Miguelez; Pavel Slampa; Michael Allgäuer; Kristina Lössl; Bülent Polat; György Kovács; Arnt-René Fischedick; Thomas G Wendt; Rainer Fietkau; Marion Hindemith; Alexandra Resch; Anna Kulik; Leo Arribas; Peter Niehoff; Fernando Guedea; Annika Schlamann; Richard Pötter; Christine Gall; Martina Malzer; Wolfgang Uter; Csaba Polgár Journal: Lancet Date: 2015-10-19 Impact factor: 79.321
Authors: Krishan R Jethwa; Sean S Park; Karthik Gonuguntla; Stephanie M Wick; Laura A Vallow; Christopher L Deufel; Thomas J Whitaker; Keith M Furutani; Kathryn J Ruddy; Kimberly S Corbin; Tina J Hieken; Robert W Mutter Journal: Int J Radiat Oncol Biol Phys Date: 2019-04-27 Impact factor: 7.038
Authors: Vonetta M Williams; Jenna M Kahn; Nikhil G Thaker; Sushil Beriwal; Paul L Nguyen; Douglas Arthur; Daniel Petereit; Brandon A Dyer Journal: Adv Radiat Oncol Date: 2020-11-06